AAP
OLMA icon

Arax Advisory Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Arax Advisory Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-564
Closed -$14.1K – 4177
2025
Q4 		$14.1K Buy
564
+559
+11,180% +$9.95K ﹤0.01% 2307
2025
Q3 		$49 Buy
+5
New +$30 ﹤0.01% 3533
2025
Q1 		– Sell
-65
Closed -$379 – 2933
2024
Q4 		$379 Buy
+65
New +$649 ﹤0.01% 2347

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Arax Advisory Partners's OLMA Position: Q1 2026 in Review

Arax Advisory Partners sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 564 shares — an estimated $14.1K sold.

Arax Advisory Partners first reported a position in OLMA in Q4 2024 and held it in 3 quarters. The position peaked at $14.1K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Arax Advisory Partners reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 564 Olema Pharmaceuticals shares in Q1 2026, an estimated $14.1K.
  • Arax Advisory Partners first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Arax Advisory Partners's Olema Pharmaceuticals position peaked at $14.1K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.